Gyre Therapeutics (GYRE) Work In Process (2022 - 2026)

Gyre Therapeutics (GYRE) has reported Work In Process for 5 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Work In Process rose 74.82% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (up 74.82% YoY), while the FY2025 annual figure was $6.3 million, up 115.33% from the prior year.
• Work In Process slipped to $6.0 million in Q1 2026 per GYRE's latest filing, from $6.3 million in the prior quarter.
• Across five years, Work In Process topped out at $6.3 million in Q4 2025 and bottomed at $2.0 million in Q4 2023.
• Historically, Work In Process has averaged $3.8 million across 5 years, with a median of $3.5 million in 2024.
• Annual changes were most pronounced in 2023 — Work In Process sank 45.54% — and 2025, when it soared 115.33%.
• Gyre Therapeutics' Work In Process stood at $3.7 million in 2022, then tumbled by 45.54% to $2.0 million in 2023, then soared by 46.67% to $2.9 million in 2024, then jumped by 115.33% to $6.3 million in 2025, then decreased by 4.98% to $6.0 million in 2026.
• Business Quant data shows GYRE's Work In Process at $6.0 million in Q1 2026, $6.3 million in Q4 2025, and $4.4 million in Q3 2025.